DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*

Similar documents
Antimicrobial Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

CHSPSC, LLC Antimicrobial Stewardship Education Series

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

Does the Dose Matter?

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Appropriate antimicrobial therapy in HAP: What does this mean?

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections

Received 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003

parameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an

Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient

Percent Time Above MIC ( T MIC)

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Principles of Antimicrobial therapy

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Postgraduate Course ERS Glasgow 2004 Antibiotics and the lung: pharmacokinetics

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Why we perform susceptibility testing

CF WELL Pharmacology: Microbiology & Antibiotics

Concise Antibiogram Toolkit Background

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

Journal of Antimicrobial Chemotherapy Advance Access published August 26, 2006

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections

CO-ACTION. Prof.dr. J.W. Mouton. Note : some technical and all results slides were removed. JPIAMR JWM Paris JWM Paris 2017

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill

Alasdair P. MacGowan*, Mandy Wootton and H. Alan Holt

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Jerome J Schentag, Pharm D

Principles of Antimicrobial Therapy

P< cells/µl mg/dl P<0.01 P<0.01

Effective 9/25/2018. Contact for previous versions.

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Introduction to Antimicrobial Therapy

crippling production of the bacterial cell wall that protects the cell from the external environment PS

Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Considerations in antimicrobial prescribing Perspective: drug resistance

Choosing an Antibiotic

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

GENERAL NOTES: 2016 site of infection type of organism location of the patient

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

Chapter 51. Clinical Use of Antimicrobial Agents

What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?

Curricular Components for Infectious Diseases EPA

ESCMID Online Lecture Library. by author

Systemic Antimicrobial Prophylaxis Issues

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Pharm 262: Antibiotics. 1 Pharmaceutical Microbiology II DR. C. AGYARE

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Animal models and PK/PD. Examples with selected antibiotics

Antimicrobial agents. are chemicals active against microorganisms

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

Other Beta - lactam Antibiotics

Approach to pediatric Antibiotics

SESSION XVI NEW ANTIBIOTICS

General Infectious Disease Concepts/Resources

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

Rational use of antibiotics

Antimicrobial Stewardship Strategy: Antibiograms

General Approach to Infectious Diseases

* gender factor (male=1, female=0.85)

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

2016 Antibiotic Susceptibility Report

Appropriate Antimicrobial Therapy for Treatment of

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Principles in antimicrobial therapy: The ABCs

OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM

2015 Antibiotic Susceptibility Report

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

Pierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

Scottish Medicines Consortium

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

January 2014 Vol. 34 No. 1

Antibiotic Usage Guidelines in Hospital

Antimicrobial susceptibility

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

SELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle

Tel: Fax:

Antibiotic Updates: Part II

Patients. Excludes paediatrics, neonates.

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS

Project Summary. Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms

Transcription:

44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine General Hospital, *Excerpt from Rational Antibiotic Use for Pediatrics, A Study Guide and Workbook KEYWORDS Äntibacterials, antibiotics, rational dosing for antibiotics OBJECTIVES Upon completion of this chapter, the learner will be able to: 1. Describe the 2 groups of antibiotics based on their bactericidal activity, namely concentration-dependent antibiotics, and time-dependent antibiotics. Name the pk/pd indices which determine efficacy. 2. Recall and define the following terms: area under the concentration vs. time curve (AUC), minimum inhibitory concentration (MIC), peak level (Cmax). 3. Classify the following antibiotics based on their bactericidal activity: penicillins, cephalosporins, aminoglycosides, vancomycin, fluoroquinolones, and carbapenems. Identify the pharmacologic indices used to determine their efficacy 4. Determine the correct dosing regimen of the above antimicrobials based on their pattern of bactericidal activity. TOPIC SUMMARY In the past, the dosing of antibiotics was largely based on habit rather than on science. In the previous decades, investigators have been able to identify pharmacological indices which facilitate comparisons of the activity of these antibiotics as well as help determine the optimal dosing regimen. For appropriate antibiotic dosing and administration, physicians must be familiar with pharmacodynamic concepts that integrate an antibiotic's microbiologic activity, pharmacokinetic properties, and mode of bacterial killing Review of Definitions The primary measure of antibiotic activity is the minimum inhibitory concentration (MIC). The MIC is the lowest concentration of an antibiotic that completely inhibits the growth of a microorganism in vitro. It is determined usually in a two-fold dilution system using either broth or agar for growth of the bacteria. The area under the curve (AUC) is a pharmacokinetic parameter which is a measure of both the extent of the drug absorbed and its persistence in the body. 1 This is the overall amount of drug in the bloodstream after a dose. It is the most reliable reflection of the extent of absorption. The C max (maximum concentration) is the highest concentration of drug in the blood that is measured after a dose. C max usually occurs within a few hours after the dose is administered. Pharmacologic Indices in antibiotics therapy Peak/MIC (Cmax (C max/mic) ratio is defined as the peak level divided by the MIC 2. It is used to predict the efficacy of concentrationdependent antibiotics. AUC/MIC is defined as the area under the curve over 24 hours divided by the MIC 2. It

45 is also used to predict the efficacy of concentration-dependent antibiotics. T>MIC is defined as the cumulative percentage of time over a 24 hour period that the drug concentration exceeds the MIC 2. It is used to predict the efficacy of timedependent antibiotics. Postantibiotic effect defined as persistent suppression of bacterial growth after a brief exposure (1 or 2 h) of bacteria to an antibiotic even in the absence of host defense mechanisms. Figure 8.1. Pharmacodynamic/Pharmacokinetic predictors of outcome. Example of single dose study of antibiotic X

Concentration Dependent Antibiotics Antibiotics can be classified based on their pattern of bactericidal activity. The first group of antibiotics is called concentration- dependent antibiotics. In this group of antibiotics, if the concentration is increased, the rate and extent of killing of bacteria is also increased. This pattern is observed in aminoglycosides and fluoroquinolones. The indices used to predict or describe this group of antibiotics are Cmax/MIC ratio and AUC/MIC ratio. Concentration dependent killing for the agents mentioned have been demonstrated in animal models and human trials. Thus increasing drug concentrations but administering it less frequently such as a single daily dose has resulted in greater cidal activity as opposed to giving the same total daily dose given several doses. These agents exhibit a prolonged postantibiotic effect and have been seen in agents which inhibit protein synthesis or nucleic acid synthesis. For aminoglycosides Cmax: MIC 10 translates into improvements in the rate and extent of clinical response. Thus Once-daily dosing (ODD) for aminoglycosides is advocated to maximise efficacy and minimise potential drug accumulation and toxicitystandard of care for adult patients. Table 8.2 shows recommended dose for aminoglycosides based on reaching the Cmax/MIC ratio of more than 10. 46 Table 8.1. 8 Classification of antibiotics based on pharmacokinetic/pharmacodynamic parameters of efficacy and bacterial eradication. Pattern of Activity Antibiotics Goal of Therapy PK/PD Parameter Type I Concentration-dependent killing and prolonged persistent effects Aminoglycosides Daptomycin Fluoroquinolones Ketolides Maximize concentrations 24h-AUC/MIC ratio Cmax/MIC ratio Type II-A Time-dependent killing and Minimal persistent effects Type II-B Time-dependent killing and Moderate to prolonged persistent effects. Carbapenems Cephalosporins Erythromycin Linezolid Penicillins Azithromycin Clindamycin Oxazolidinones Tetracyclines Vancomycin Maximize duration of exposure Maximize amount of drug T>MIC 24h-AUC/MIC ratio Table 8.2.2. Dose of aminoglycosides to achieve a Cmax/MIC ratio >10 ClCr Gentamicin Amikacin >50 5 mg/kg/24 hrs 15 mg/kg/24 hrs 30-49 5 mg/kg/36 hrs 15 mg/kg/36 hrs 20-29 5 mg/kg/48 hrs 15 mg/kg/48 hrs <20 2 mg/kg with monitoring 7.5 mg/kg with monitoring

47 Figure 8.2. Representative Time-kill curves of Concentration Dependent Antibiotic in In vitro Models Log10 cfu/ml 10 8 6 4 2 0 0 2 4 6 Time (hr) Control 1/4 MIC 1x MIC 4xMIC 16XMIC 64XMIC There are some groups of patients wherein in the once-daily dosing is not applicable since their pharmacokinetics may differ or if gram positive organisms are targeted. These groups include patients with ascites, patients with burns involving >20% body surface area, pregnant patients, patients on dialysis, patients treated for suspected or documented endocarditis, and patients treated for staphylococcal and enterococcal infections when aminoglycoside therapy is used for synergy. For fluoroquinolones numerous studies (both in animal models and humans) have shown that optimal AUC:MIC ratios result in better outcomes. It has also been noted that the optimal AUC:MIC ratio varied with different organisms. For nosocomial pneumonia treated with ciprofloxacin, AUC:MIC >125 results in clinical cure and bacteriological eradication rates >80%. For community-acquired pneumonia treated with levofloxacin or gatifloxacin, AUC:MIC >34 improve the probability of pneumococcal bacteriological eradication. Quinolones are usually dosed once or twice daily. Time Dependent Antibiotics The second group of antibiotics is called time ime-dependent antibiotics which kills bacteria at the same rate and to the same extent after reaching a threshold concentration. Thus these drugs kills bacteria only when concentration at the site is higher than the MIC, but once the concentration at the bacterial site is more than 4 times the MIC, the additional killing is only modest. The extent of bacterial killing is dependent on time of exposure because these agents have very short or no postantibiotic effect especially for gram negative organisms. Thus the goal of therapy in this group is to maintain serum concentrations above the MIC for as long as possible during the dosing intervals. For this second group of antibiotics the most important pharmacologic index is T>MIC which has been proven in numerous in vitro and in vivo models as wells as observed in human trials. Included in this group are beta lactams, clindamycin, linezolid and vancomycin. At the moment there is no agreement on the optimal value of the T>MIC, observational studies have shown that values of % duration T>MIC is the minimum

goal in dosing for penicillins and cephalosporins. This would lead to at least stasis of most target bacteria. Values of T>MIC of >70% is ideal to maximize killing of the bacteria, while some investigators suggest achieving a T>MIC of 100% to prevent bacterial resistance. There are several ways by which you can increase the T>MIC. These include: 1)increasing the dose, 2)increasing the dosing frequency, 3) improving the pharmacokinetic profile (such as extended-release formulations), 4)increasing the duration of infusion or by giving parenteral drugs by continuous infusion; and 5) use another drug (e.g. probenecid) that interferes with elimination. Thus, most drugs in this group with short half lives may be given every 4-6 hrs, or as continuous infusion depending on the stability of the drug. 48 Figure 8.3.. Representative Time-kill curves of Time Dependent Antibiotic in In vitro Models 10 Log10 cfu/ml 8 6 4 2 0 0 2 Time 4(hr) 6 8 Control 1/4 MIC 1x MIC 4xMIC 16XMIC 64XMIC Figure 8.4. Pharmacodynamic Goals (T>MIC as percent of Interval) with Beta-Lactams Class Organism Stasis (T>MIC) Maximum killing (T>MIC) Cephalosporins Gram neg bacilli, pneumococcus Staphylococcus 20-30 70-80 Penicillins Gram neg bacilli, pneumococcus 30-40 60-70 Carbapenems Staphylococcus Gram neg bacilli. Staphylococcus pneumococcus 20-30 20-30 10-20 25-40

49 Table 8.3. Preferred Dosing Regimens for Children for Selected Antibiotics based on PK-PD Classification Antibiotic Classification Total dose Dosing Frequency per day (mg/kg) Amikacin *CD 15 Once daily Gentamicin CD 5 Once daily Penicillin **TD 100,000-200,000 Every 4 hrs Cefazolin TD 50-100 Every 6-8 hrs Cefuroxime TD 75-150 Every 6-8 hrs Ceftriaxone TD 100 Every 12-24 hrs Ceftazidime TD 100-150 Every 8 hrs, or continuous infusion Piperacillintazobactam TD 240-400 Every 8 hrs or continuous infusion Meropenem TD 60-120 Every 8 hrs as bolus or infused over 3 hrs *concentration dependent **time-dependent Bibliography: Textbook of pediatric infectious diseases, edited by Feigin, R. et al. 5 th Edition. Saunders, Pennsylvania 2004; Chapter 234 Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99 DP Nicolau, CD Freeman, PP Belliveau, CH Nightingale, JW Ross, R Quintiliani. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother Mar 01, 1995; 39: 650-655 A Forrest, D E Nix, C H Ballow, T F Goss, M C Birmingham, and J J Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. May 1993, 37: 1073-1081 Paul G. Ambrose, Dennis M. Grasela, Thaddeus H. Grasela, Julie Passarell, Howard B. Mayer, and Phillip F. Pierce. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community- Acquired Respiratory Tract Infections. Antimicrob Agents Chemother. October 2001 45: 2793-2797 Quintiliani R Sr, Quintiliani R Jr, Pharmacokinetics/Pharmacodynamics macodynamics for Critical Care Clinicians. Critical Care Clinicians 2008, 24: 335-348. Amsden GW, Ballow CH, et al. Pharmacokinetics and Pharmacodynamics of Anti-infective agents, Principles and Practice of Infectious Diseases, 7 th Edition. Vol. 1, Churchill Livingstone, Philadelphia, 2010, Chapter 20. Internet Resources Rxkinetics. <wwww.rxkinetics.com/antibiotic_pk_pd.html> Gunderson BW et al. What do we really know about Antibiotic Pharmacodynamics Pharmacotherapy 21(11s)2001;302s-318s. <http://www.medscape.com/viewarticle/415068_print > Jo Carol J. McNabb, Charles H. Nightingale., Richard Quintiliani, and David P. Nicolau. Cost-Effectiveness of Ceftazidime by Continuous Infusion versus Intermittent Infusion for Nosocomial Pneumonia. Pharmacotherapy 21(5):549-555, 2001. <http://www.medscape.com/viewarticle/409720>